Half-Year 2022 Financial and Clinical Trials Update

Alecensa Global sales CHFbn CER growth +19% Regional sales CER growth US +19% 0.8 0.7 0.6 Europe +7% 0.5 0.4 Japan +6% 0.3 0.2 0.1 International +37% 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 745m • US: New patient share in 1L at around 70% • • EU: EU-5 new patient share in 1L at around 70% Japan: New patient share in 1L reaching >70% International: Strong growth driven by China CER-Constant Exchange Rates Roche 180

View entire presentation